Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts.
Clinical Trial Grant
Duke Scholars
Principal Investigator
Danielle Marie Brander
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
TG Therapeutics, Inc
Start Date
March 1, 2015
End Date
February 28, 2022
Awarded By
TG Therapeutics, Inc
Start Date
March 1, 2015
End Date
February 28, 2022
